{
    "clinical_study": {
        "@rank": "13276", 
        "arm_group": {
            "arm_group_label": "Single Arm", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate a new ceramic metal bone graft substitute for hemi\n      craniectomies. The frequency of infections and rupture of skin will be studied, which is a\n      reoccurring problem with currently used bone graft substitutes in this subject population.\n      In addition, the quality of life before and after implantation will be evaluated as well as\n      the bone regeneration around implant."
        }, 
        "brief_title": "Bone Reconstruction of the Skull Using a Metal Ceramic Implant After Previously Failed Reconstruction", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Defect of Skull Ossification", 
            "Other Specified Skull or Face Bone Anomaly", 
            "Cranial Dysostosis Nec", 
            "Hemicraniectomy"
        ], 
        "condition_browse": {
            "mesh_term": "Dysostoses"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Obtained informed consent.\n\n          -  Males or females, \u226518 years of age\n\n          -  Subject with cranial defect size > 25 cm2.\n\n          -  History of previous cranial implant failure and where the latest cranial\n             reconstruction failed within 12 months. (This means that the patient demonstrates a\n             non-reconstructed cranial defect after removal of implant or exhibit an implant\n             failure, e.g. local infection and/or protrusion through the skin.)\n\n          -  Willing and able to comply with all study procedures and restrictions.\n\n          -  The 5 subjects participating in bone regeneration analysis (PET/CT scans) has to be\n             50 years or older\n\n        Exclusion Criteria:\n\n          -  Malignancy adjacent to the reconstruction area, including brain and calvaria, with\n             on-going or planned surgical intervention.\n\n          -  Pregnant or nursing women.\n\n        Exclusion criteria during surgery, if applicable:\n\n        Perioperative appearance of previously not identified tumor or infection in the\n        reconstruction area."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "11", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01899807", 
            "org_study_id": "OQ-CR-001"
        }, 
        "intervention": {
            "arm_group_label": "Single Arm", 
            "intervention_name": "OssDsign AB", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 26, 2014", 
        "location": [
            {
                "contact": {
                    "email": "magnus.tisell@vgregionen.se", 
                    "last_name": "Magnus Tisell, MD, PhD", 
                    "phone": "+46734002029"
                }, 
                "facility": {
                    "address": {
                        "city": "Gothenburg", 
                        "country": "Sweden", 
                        "zip": "413 45"
                    }, 
                    "name": "Dept. of Neurosurgery, Sahlgrenska University Hospital"
                }, 
                "investigator": {
                    "last_name": "Magnus Tisell, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lars.kihlstr\u00f6m@karolinska.se", 
                    "last_name": "Lars Kihlstr\u00f6m, MD,MBA,FRCPS", 
                    "phone": "+46736251801"
                }, 
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }, 
                    "name": "Dept. of Neurosurgery, Karolinska Universitetssjukhuset"
                }, 
                "investigator": [
                    {
                        "last_name": "Lars Kihlstr\u00f6m, MD,MBA,FRCPS", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Kalle Lundgren, MD, PhD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "1", 
        "official_title": "Cranial Reconstruction With Patient-specific Titanium Mesh/Mosaic-designed Calcium Phosphate-implant - A Multi Center Center, Single Arm, Non-comparative Prospective Case Series", 
        "other_outcome": {
            "description": "Mean number of hospital days, hospital visits, mean time to adverse event and lost work days related to the study treatment  will be counted.", 
            "measure": "Health economy variables", 
            "time_frame": "3 months and 12 months post intervention compared to baseline visit: 3-0 weeks pre intervention"
        }, 
        "overall_contact": {
            "email": "lars.kihlstom@karolinska.se", 
            "last_name": "Lars Kihlstr\u00f6m, MD, MBA", 
            "phone": "+46 73 6251801"
        }, 
        "overall_contact_backup": {
            "email": "kalle.lundgren@ki.se", 
            "last_name": "Kalle Lundgren, MD, PhD", 
            "phone": "+46 739824349"
        }, 
        "overall_official": [
            {
                "affiliation": "Department of Neurosurgery, Karolinska University Hospital", 
                "last_name": "Lars Kihlstr\u00f6m, MD, MBA", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Karolinska University Hospital", 
                "last_name": "Kalle Lundgren, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint, rate of adverse events, will be measured by clinical evidence of infection and/or manifested rupture of skin around the implant, within 12 months, that necessitates explantation.", 
            "measure": "Rate of adverse events", 
            "time_frame": "From the date of intervention up to 12 months post intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01899807"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska University Hospital", 
            "investigator_full_name": "Dr. Kalle Lundgren", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage subjects with an adverse event", 
                "time_frame": "From the date of intervention up to 14 days, 3 months, 6 months follow-up"
            }, 
            {
                "description": "SF-12 and EQ5D 3L will be used", 
                "measure": "Quality of life scores", 
                "time_frame": "Assessed during the 3 month- and 12 month follow-up visit post intervention, compared to the screening visit: 3-0 weeks prior to intervention"
            }, 
            {
                "description": "The bone tracer (18 F fluoride) will be used to measure bone regeneration.", 
                "measure": "PET/CT analysis with bone tracer, confirms bone regeneration activity within the reconstruction area", 
                "time_frame": "The PET/CT scan will be taken at 12 months post intervention and it will be compared with 2 weeks post intervention"
            }, 
            {
                "description": "Subject cognitive impairment is measured by Montreal Cognitive Assessment (MOCA) (the subject will be given a score after completing the assessment)", 
                "measure": "Subject mean MOCA", 
                "time_frame": "3 months and 12 months follow-up compared to baseline"
            }
        ], 
        "source": "Karolinska University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karolinska University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}